Dyncorp has many faces. The contractor is involved in an assortment of (above board) services worldwide, the vast majority of their business comes from large government contracts issued by US government agencies (USAID, State Department, Department of Defense).
In previous posts, I have highlighted how Dyncorp provided police personnel, police force training, prison construction and the contractor’s involvement in the CIA extraordinary rendition program. Much of my previous posts were focused on Haiti in particular, I intend on returning to the subject of Haiti in upcoming posts, but for now I want to discuss Dyncorp’s involvement in the development of vaccines.
Officially, Dyncorp is no longer in the business of researching and developing vaccines because it sold their subsidiary to another company CSC in 2003 and 2004.
In the not so distant past, Dyncorp created a joint venture with Porton International (UK) that became DynPort, later known as DVC (Dynport Vaccine Company LLC). Here is a brief history of DVC ownership from 1997 to 2017.
Today Dynport is owned by CSRA. CSRA headquarters is located about a 10 minute drive from Dyncorp International headquarters. Curiously enough, Dyncorp's parent company Delta Tucker Holdings LLC is literally next door to CSRA in Falls Church, Virginia.
Dyncorp/Dynport’s involvement with vaccination programs is both eye opening and disturbing.
Here’s how the CSRA website describes DVC.
For those familiar with Dyncorp, it will come as no surprise that Dynport focussed on developing technologies for the military working closely with government agencies such as the Laboratory of Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Health (NIH) on vaccinations concerned with ‘biodefence’.
Here is a quick summary of some of the vaccines Dynport developed (or has been researching):
• Flu vaccine
• Small Pox vaccine
• Anthrax vaccine
• Tularemia vaccine
• Plague vaccine
• Swine Flu (H1N1) vaccine
• Nerve Agent vaccine (prophylactics)
Before teaming up with Dyncorp, Porton (UK) had created a US branch of their company know as BioPort. In the 1990s it had become one of a small minority of companies with the ability to produce an anthrax vaccine.
According to this October 2001 Salon.com article, The Anthrax Vaccine Scandal, BioPort executives were able to secure government contracts over more experienced companies even though their facilities were substandard, their finances were instable and they were accused of leveraging the close ties to the DoD and Pentagon of one of their executives to win favor.
In 1997, DynCorps partnered with the El-Hibris’ old company Porton International, to form DynPort Vaccine Company (DVC), just in time to beat out four other bids for a $322 million, 10-year contract.
Under the award, “DVC acts as a prime system contractor for the management of the existing stockpile of biological defense vaccines (except anthrax vaccine) and the advanced development, testing, production, FDA licensure, and storage of up to 18 new biological defense vaccines, including new vaccines against anthrax, small pox, plague, botulism and tularemia,” according to Pentagon spokesman Jim Turner.
The newly formed DynPort would continue to garner lucrative government contracts for development of Flu vaccines.
The company would go on to be acquired by CSC and become involved in further questionable activities regarding their research and development.
In a 2009 article that describes Dyncorps involvement in the vaccination business, Naturalnews.com writer Mike Adams states that an integral ingredient in developing a working vaccine, is the diseased flesh of African Green Monkeys. He cites US patent #5911998 -Method of producing a virus vaccines from am African Green Monkey kidney cell line.
http://www.patents.com/us-5911998.html
DynCorp is reported to have 4 patents relating to viruses and vaccines
Original Natural News Article
The article goes on to say more about DVC
One of the key inventors in these patents now held by DynCorp was Dr. Robert H. Purcell. Who is Dr. Robert Purcell? He's one of the co-chiefs of the Laboratory of Infectious Diseases of the National Institute of Allergy and Infectious Diseases operating under the National Institutes of Health of the U.S. government. (http://www3.niaid.nih.gov/labs/aboutlabs/lid...)
That office, located at 50 South Drive, Bethesda, MD 20892, is less than 15 miles away from the headquarters of DynCorp.
It's not too many more miles to Washington D.C., where U.S. government health authorities awarded over $1 billion in swine flu vaccine contracts to pharmaceutical companies. Can you guess which company received one of the largest vaccine manufacturing contracts? Baxter Pharmaceuticals, the very same company using ingredients derived from African Green Monkeys in precisely the way described in the patents held jointly by DynCorp and the NIH. Remember, Baxter is the company that was caught inserting live viruses into vaccine materials distributed to 18 different countries.
Are you following all this?
So far, we have the U.S. government awarding swine flu vaccine manufacturing contracts to a major U.S. vaccine manufacturer (Baxter) that uses vaccine ingredients from African Green Monkeys (sick!), derived from a process covered in a patent invented by U.S. government NIH researchers (Dr. Purcell and others) and now held jointly by the NIH and a private military contractor named DynCorp -- the very same company that's paid to monitor the U.S. / Mexico border where H1N1 swine flu first appeared.
The article raises some good questions:
- Given Baxter Pharmaceuticals atrocious record for handling materials, why were they contracted by the government?
- Why would the inventors of a key vaccine technology agree to hand over ownership of the patent to a private military contractor like DynCorp?
- How much money is DynCorp collecting on the vaccine patents due to the sudden large-scale manufacture of swine flu vaccines taking place right now?
- Why does the U.S. government continue to do business with criminally-minded organizations and incompetent vaccine manufacturers?
The suggestion is put forth that considering DynCorps track record of human trafficking, defrauding the government of millions in bogus billing, drug eradication/fumigation in Columbia, involvement in CIA extraordinary rendition program and human trafficking in Kosovo and Bosnia…
is it possible that DynCorp, the NIH and Baxter created the H1N1 swine flu?
The swine flu first appeared at the US/Mexican border, quickly followed by dire warnings of a possible (pandemic) epidemic that could infect hundreds of thousands.
When dire public health warnings are made, such as the fear behind the possible spread of swine flu, the result is that vaccines are quickly purchased and stock piled to guard against the worst case scenario.
As we can plainly see, the first patent on the list owned by DynCorp is #6025182 entitled “Method for producing a virus…” while another patent, #5911998, clearly shows that DynCorp also created a vaccine specifically for the African green monkey virus.
Was H1N1 intentionally created to generate huge profits for vaccine developers and patent holders?
Given that we are all somewhat familiar with DynCorp’s shady activities we can focus here on Baxter pharmaceuticals. Not surprisingly, Baxter has a less than perfect track record in the industry and has a long list of controversies.
https://en.wikipedia.org/wiki/Baxter_International
- 1975 Hemofil - Hepatitis B outbreak
- 1983 Prison Plasma Collection
- 1996 Japanese Haemophiliac HIV Lawsuit
- 2001 Althane disaster
- 2008 Chinese heparin adulteration
- 2009 Avian flu contamination
- 2009 drug cost inflation
- 2010 Hepatitis C infections
- 2010 infusion pump recall
- 2008–2010 tax dodging
Looks like Baxter and DVC are a perfect match.
Here are a few contracts and subcontracts that DVC has been involved with more recently –
The development of a Nerve Agent by AIBio receiving a subcontract from DVC.
This is a 3 million dollar contract that seems to be standard fare on the surface but if we compare it to DVC developments it becomes more relevant.
In 2007, DVC and Baxter pharmaceuticals team up once again for the development of ‘Bioscavenger’, designed to prevent or treat the effects of exposure to certain nerve agents.
From globalbiodefense.com the BioScavenger contract is estimated at close to $150 million USD.
https://globalbiodefense.com/2013/05/13/notable-contracts-dynport-nerve-agent-countermeasure-development/
The U.S. Army has been researching naturally occurring human enzyme called butyrylcholinesterase for their potential as a chemical agent countermeasure. Nicknamed “BioScavenger,” the enzyme works by capturing the nerve agent as it enters the body, before it can reach its physiological target and negating the danger.
In 2005, the U.S. Department of Defense (DoD) Chemical Biological Medical Systems – Medical Identification and Treatment Systems (CMBS-MITS), building on the work of Army scientists, awarded a contract to DynPort for further advance development of human plasma-derived BioScavenger as a pre-exposure therapeutic, or prophylactic, against chemical nerve agents.
Do you see a pattern here?
Sarin Gas is specifically identified here. Sarin gas has been used in Syria with both rebel and government soldiers being accused of using the chemical agent. The US government accused Asad (president of Syria) of committing war crimes and was poised to use the Sarin gas attacks as a pretext for war. However, since then it has been proven that the Sarin strand originated from Libya and provides evidence for Sy Hersh’s claims to the Red lines / Rat lines smuggling of weapons/oil between Libya and Syria through Turkey. (See George Webb Series YT).
It would appear that DVC is profiting quite handsomely from seemingly unpredictable global events. The biohazardous threats they are working on in their R&D pipelines seem to be predicted quite accurately by the company.
It must be a coincidence or just a cold assessment made by the sober minds at DVC.
It may surprise you then that Dyncorp was awarded a major contract in Liberia in 2010 for $20 million USD. This is on top of their $1.5 billion USD contract AFRICAP awarded in 2009.
Was there some sort of biohazard in western Africa in recent times?
Hhmm…what was it again?
Oh yeah…
EBOLA.
This 2014 report displays a long list of health and pharmaceutical companies involved in the development of an Ebola vaccine and low and behold, DVC is among those listed.
As of 2015, apparently 2 competing companies were chosen as test vaccines: GlaxoKlineSmith and PHAC (aptly named).
That being said, is it truly a coincidence that wherever DynCorp is present or has contracts, there is death and destruction? Dyncorp positions itself in the middle of it all, waiting to profit off the carnage.
It’s no comfort knowing that DynPort is conducting R&D into a PLAGUE VACCINE.
